Agena Bioscience today expanded its European distributors through new relationships with KAWA.SKA in Poland and BioGen-Analytica in Russia.

“We are pleased to extend our partnerships with BioGen-Analytica and KAWA.SKA not only for their experience in the biotechnology market, but also for their ability to move Agena Bioscience into the clinical and diagnostic markets. We are excited to be working with both of these companies to help better meet the growing market demand from our Eastern European customer base,” said Edvin Munk, Agena Bioscience’s Vice President and Managing Director, Europe.

“We chose Agena Bioscience because the company and its MassARRAY System fits very well into KAWA.SKA’s product portfolio to provide a more comprehensive solution for our clinical customer base – from sample to results,” said Marian Kawczynski, President of KAWA.SKA.

KAWA.SKA in Poland serves hospitals, medical academies, the Polish Academy of Sciences institutes, molecular diagnostics facilities, biotechnology companies, and industrial plants.

“Agena Bioscience’s MassARRAY System aligns with the future of medical science, and has great potential in the diagnostic market in Russia,” said Dr. Andrey Glubokov, Director of BioGen-Analytica.

BioGen-Analytica in Russia serves top universities, medical academies, federal agencies including the ministry of defense, and drug developers.

Agena Bioscience’s other European distributors include Diatech Pharmacogenetics, Bio-Consult, Antisel, BioBusiness Technology, ADVANSYS, MBM Tibbi Malzemeler Tic. Ltd. Sti. and Omnivet Impex S.R.L.

The MassARRAY System detects genetic variation directly by end-point PCR and label-free mass spectrometry. Due to the high confidence level mass spectrometry provides, the MassARRAY System is used to screen for targeted biomarkers implicated in a number of clinical applications including carrier screening, oncology, pharmacogenomics, and newborn screening.

The platform’s rapid and flexible assay design coupled with simple data analysis allows laboratories to develop targeted, actionable panels for routine or specialized assays with limited bioinformatics resources for as little as tens of EURO per test.